AMR Vocabulary
| Term | Definition |
|---|---|
| GOV | Governmental Entities |
| GP | General practitioner |
| GR | Genotypic resistance |
| Gram | Gram-negative indicates a group of bacteria that become red when the bacterial cells are treated using the Gram stain method. This response is based on the chemical and physical properties of their cell walls and is used to identify the type of bacteria. Gram-positive indicates a group of bacteria that become blue when the bacterial cells are treated with the Gram stain. |
| HABP | Hospital-acquired bacterial pneumonia |
| HAI | Healthcare-associated infections |
| HAP | Hospital-acquired pneumonia |
| HCAP | Healthcare-associated pneumonia |
| HCPs | Healthcare Practitioners |
| HFMA | Healthcare Financial Management Association |
| HIS | Hospital Information System |
| HITSP | Healthcare Information Technology Standards Panel, USA |
| HMP | Human medicinal product |
| HPA | Health Protection Agency, UK equivalent of the American CDC |
| HPC | High-performance computing |
| HS | Hospital Innovation Representatives |
| ICT | Information and Communication Technologies |
| ICU | Intensive care unit |
| IFR | Institut for Rationel Farmakoterapi |
| IHI | Institute for Healthcare Improvement |
| IHR | International Health Regulations |
| IM | Intramuscular |
| IMP | Imipenemase |
| iMPV | Inhaled murepavadin |
| IND | Investigational new drug |
| IPC | "Infection Prevention and Control" is a practical, evidence-based approach that stops patients, health workers, and visitors from catching avoidable infections in healthcare settings. |
| IPO | Initial Public Offering |
| IQWiG | Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen |
| IS | Implementation Science |
| ISV | Independent software vendor |
| ITT | Intent-to-treat |
| iv | Intravenous |
| IVD | In-vitro Diagnostics |
| JPIAMR | Joint Programming Initiative on AMR |
| K-res | Norwegian Centre for Detection of Antimicrobial Resistance |
| KOL | Key Opinion Leader |
| KPC | Klebsiella pneumoniae carbapenemase |
| LIC | Low-income Country |
| LIMS | Laboratory Information Management System |
| LMICs | Low- and middle-income countries |
| LOI | Letter of Intent |
| LOS | Length of stay |
| LRE | Linezolid resistant enterococci |
| LVRE | Linezolid and vancomycin resistant enterococci |
| MAA | Marketing authorization application |
| mAb | Monoclonal antibody |
| MAD | Multiple ascending dose |
| MBL | Metallo-β-lactamase |
| MBO/MBI | Management buy-out, or buy-in |
| MD | Medical Devices |